MAGEF1 Antibody | 62-159

MAGEF1 Antibody | 62-159 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: This MAGEF1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 274-303 amino acids from the C-terminal region of human MAGEF1.

Research Area: Cancer

Tested Application: WB, IHC-P

Application: For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 35 kDa

Validation: N/A

Isoform: N/A

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis

Clonality: Polyclonal

Clone: N/A

Isotype: Rabbit Ig

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.

Concentration: batch dependent

Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Melanoma-associated antigen F1, MAGE-F1 antigen, MAGEF1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Melanoma-associated antigen (MAGE) are completely silent in normal tissues, with the exception of male germ cells, and, for some of them, placenta. These antigens ought to be strictly tumor specific, expressed in tumor cells of various histological types. Because of their specific expression on tumor cells, these antigens are of particular interest for antitumor immunotherapy. Genes of the MAGE family direct the expression of tumor antigens that are recognized on a human melanoma by autologous cytolytic T lymphocytes. Though the function of MAGE is unknown, may play a role in embryonal development and tumor transformation or aspects of tumor progression.